← All agents | ← Research tracker
Rituximab
PubChem entry
Evidence Summary
Evidence Level: Moderate
Mechanism: Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other, Unknown / General
Safety: Infusion reactions, serious infections (including PML risk), hepatitis B reactivation, hypogammaglobulinemia. Requires specialist oversight, screening, monitoring.
Dosing: Typical rheumatology regimens 1000 mg IV x2 (2 weeks apart) or 375 mg/m² weekly x4; ME/CFS trials used similar; repeat as needed.
Anti-CD20 studied in ME/CFS (mixed prior). Several trials. Serious infection risk. Specialist use only for clear autoimmune subsets. 5 trial associations.
Related Conditions
ME/CFS (no page yet)
Clinical Trials
5 trial(s) registered
NCT06952413: Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) PHASE2 RECRUITING
NCT01156922: B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome PHASE2 TERMINATED
NCT02229942: B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. PHASE3 COMPLETED
NCT00848692: Drug Intervention in Chronic Fatigue Syndrome PHASE2 COMPLETED
NCT01156909: B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome PHASE2 COMPLETED
Key Studies / References